未来新疫苗引入的优先排序:埃塞俄比亚国家免疫技术咨询小组的经验
埃塞俄比亚国家免疫技术咨询小组使用新疫苗引入优先排序与测序工具(NVI-PST)对六种候选疫苗进行多标准决策分析,将六价疫苗和风疹疫苗列为最高优先早期引入,RSV和MMCV为中等优先,TCV和OCV为较低优先。该过程标志着该国免疫决策从被动一次性评估转向战略性系统化方法。
要点
- 六价疫苗和风疹疫苗因公共卫生重要性与规划可行性综合评分最高,被列为最高优先早期引入。
- RSV和MMCV被列为中等优先,TCV和OCV被列为常规免疫较低优先。
- ENITAG强调加强秘书处、改善数据系统并在未来优先排序中整合社区视角。
核心结论
- 该实践标志着埃塞俄比亚免疫决策从被动、一次性的疫苗评估转向与国家优先事项和卫生系统能力相一致的战略性系统化方法。
- 尽管存在数据质量和资源限制方面的挑战,该过程为其他寻求以透明、循证方式优化免疫投资的低收入国家提供了可复制的模式。
研究设计与样本
- 埃塞俄比亚国家免疫技术咨询小组(ENITAG)与联邦卫生部(FMoH)及合作伙伴合作,将新疫苗引入优先排序与测序工具(NVI-PST)适配至埃塞俄比亚国情。
- 六种候选疫苗被列入短名单:六价疫苗、风疹(MR)疫苗、多价脑膜炎球菌结合疫苗(MMCV)、伤寒(TCV)疫苗、霍乱(OCV)疫苗和呼吸道合胞病毒(RSV)疫苗。
- 选取并加权了重要性和可行性两个领域的十三项标准。
- 数据由专题工作组收集,并通过涉及ENITAG成员和利益相关方的参与式过程对每种疫苗进行评分和排序。
主要发现
- 六价疫苗和风疹疫苗因公共卫生重要性和规划可行性的综合评分最高,被列为最高优先早期引入。
- RSV和MMCV被列为中等优先。
- TCV和OCV被列为常规免疫较低优先。
- 建议考虑了现有规划限制,如即将引入的疫苗(例如疟疾、黄热病、乙肝出生剂次)和补充免疫活动。
- ENITAG还强调加强其秘书处、改善数据系统并在未来优先排序工作中整合社区视角。
关键数值与推荐
- 六种候选疫苗:六价疫苗、风疹(MR)疫苗、多价脑膜炎球菌结合疫苗(MMCV)、伤寒(TCV)疫苗、霍乱(OCV)疫苗和呼吸道合胞病毒(RSV)疫苗。
- 十三项标准跨重要性和可行性两个领域被选取并加权。
- 六价疫苗和风疹疫苗被列为最高优先早期引入。
- RSV和MMCV被列为中等优先。
- TCV和OCV被列为常规免疫较低优先。
临床怎么用
- 原文未据此给出推荐。
局限性
- 存在与数据质量和资源限制相关的挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As Ethiopia faces growing demands to introduce new vaccines amid constrained resources and declining donor support, evidence-based prioritization is essential. This paper describes the experience of Ethiopian National Immunization Technical Advisory Group's (ENITAG) in using a structured, multi-criteria decision analysis (MCDA) approach-the New Vaccine Introduction Prioritization and Sequencing Tool (NVI-PST)-to guide new vaccine introduction and sequencing for the 2026-2030 period. METHODS: ENITAG, in collaboration with the Federal Ministry of Health (FMoH) and partners, adapted the NVI-PST to Ethiopia's context. Six candidate vaccines were shortlisted-hexavalent, rubella (MR), multivalent meningococcal conjugate (MMCV), typhoid (TCV), cholera (OCV), and respiratory syncytial virus (RSV) vaccines. Thirteen criteria across importance and feasibility domains were selected and weighted. Data were gathered by thematic working groups and used to score and rank each vaccine through a participatory process involving ENITAG members and stakeholders. RESULTS: The hexavalent and rubella vaccines were prioritized the highest for early introduction due to their combined public health importance and programmatic feasibility. RSV and MMCV were ranked as medium priorities, while TCV and OCV were deemed lower priorities for routine immunization. The recommendations considered existing programmatic constraints, such as upcoming introductions (e.g., malaria, yellow fever, hepatitis B birth dose) and supplementary campaigns. ENITAG also emphasized strengthening its secretariat, improving data systems, and integrating community perspectives in future prioritization efforts. CONCLUSION: This exercise marks a pivotal shift in Ethiopia's immunization decision-making-from reactive, one-off vaccine assessments to a strategic, systematic approach aligned with national priorities and health system capacity. Despite challenges related to data quality and resource limitations, the process offers a replicable model for other low-income countries seeking to optimize immunization investments in a transparent, evidence-informed manner.
引用
- Memirie ST, Teka T, Mekasha A, et al. Prioritization of future new vaccines introduction: The experience of the Ethiopian National Immunization Technical Advisory Group. Vaccine. 2025. PMID: 41176965. doi:10.1016/j.vaccine.2025.127932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。